Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AYTU
AYTU logo

AYTU Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Aytu Biopharma Inc (AYTU) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.250
1 Day change
5.88%
52 Week Range
3.060
Analysis Updated At
2026/06/05
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

AYTU is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The available data does not show a strong technical setup, no Intellectia trading signals are active, and there is no supportive valuation, options, news, analyst, or financial momentum data strong enough to justify an immediate purchase. Based on the current information, the best direct call is to hold off rather than buy now.

Technical Analysis

Technical analysis is limited because the stock trend data could not be fetched. The only available price context is that AYTU is trading with the market at 0% change versus the S&P 500, which does not indicate relative strength or a confirmed upward trend. With no trend confirmation, no recent signal, and no momentum evidence, the current price action does not provide a clear long-term entry point.

Positive Catalysts

  • No active Intellectia proprietary bullish signals are present. AI Stock Picker shows no signal today, and SwingMax also shows no recent signal. No recent congress buying is available. There is no valuation data, so no visible catalyst from undervaluation can be confirmed.

Neutral/Negative Catalysts

  • No signal on given stock today. Stock trend data is unavailable, leaving no technical confirmation of strength. No recent congress trading data is available. No valuation data is provided. No news summary, analyst upgrades, or price target increases are available to support a bullish view. No options sentiment data is available to indicate strong trader interest.

Financial Performance

No financial data was provided, so the latest quarter financial performance and growth trends cannot be assessed. The latest quarter season is not available from the supplied data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided. As a result, there is no evidence of improving Wall Street sentiment, and the current pros and cons view leans negative simply because the stock lacks supportive analyst conviction.

Wall Street analysts forecast AYTU stock price to rise
3 Analyst Rating
Wall Street analysts forecast AYTU stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.125
sliders
Low
7
Averages
9.33
High
13
Current: 2.125
sliders
Low
7
Averages
9.33
High
13
Maxim
Buy
maintain
$9 -> $7
AI Analysis
2025-09-25
Reason
Maxim
Price Target
$9 -> $7
AI Analysis
2025-09-25
maintain
Buy
Reason
Maxim lowered the firm's price target on Aytu BioPharma to $7 from $9 and keeps a Buy rating on the shares. The firm cites the company's Q4 and adjusted EBITDA miss, and while the quarter was the 9th straight quarter of positive adjusted EBITDA, its base business - ADHD+pediatrics - has effectively peaked, the analyst tells investors in a research note. Maxim adds however that in June, Aytu announced it signed an exclusive commercialization agreement with Fabre-Kramer Pharmaceuticals to commercialize EXXUA, and the firm believes that EXXUA is a transformational asset that can accelerate growth beyond the current ADHD franchise.
Maxim
Buy
downgrade
$9 -> $7
2025-09-24
Reason
Maxim
Price Target
$9 -> $7
2025-09-24
downgrade
Buy
Reason
Maxim lowered the firm's price target on Aytu BioPharma to $7 from $9 and keeps a Buy rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for AYTU
Unlock Now

People Also Watch